Evidence map›Paper›PMID 41589138›Full record

ArticleCureus2025

Effect of Nitisinone on Aortic Stenosis Disease Progression in Patients With Alkaptonuria: An Analysis of the Suitability of Nitisinone in Alkaptonuria (SONIA) 2 Study.

Callum Bruce, Priyanka Meenamkuzhy-Hariharan, Shahdat Hussain, Antonio Eleuteri, Lakshminarayan Ranganath, Michael Fisher, Richard Imrich, Jean-Baptiste Arnoux, Birgitta Olsson, Mattias Rudebeck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Callum BruceInternal Medicine, Royal Liverpool University Hospital, Liverpool, GBR.
Priyanka Meenamkuzhy-HariharanInternal Medicine, Countess of Chester Hospital, Chester, GBR.
Shahdat HussainCardiology, Aintree University Hospital, Liverpool, GBR.
Antonio EleuteriMedical Physics and Clinical Engineering, Royal Liverpool University Hospital, Liverpool, GBR.
Lakshminarayan RanganathClinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Liverpool, GBR.
Michael FisherCardiology, Royal Liverpool University Hospital, Liverpool, GBR.
Richard ImrichInstitute of Clinical and Translational Research, Slovak Academy of Sciences, Bratislava, SVK.
Jean-Baptiste ArnouxPaediatric Metabolic Disease, Hôpital Necker-Enfants malades, Paris, FRA.
Birgitta OlssonPharmaceuticals, Gariguella AB, Ekerö, SWE.
Mattias RudebeckPharmaceuticals, OnPoint Science AB, Stockholm, SWE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim Alkaptonuria (AKU) is a rare metabolic disorder characterised by the accumulation of homogentisic acid (HGA). Deposition of HGA in the aortic valve leading to progressive aortic stenosis is a serious complication. Nitisinone has been shown to improve morbidity and slow disease progression in AKU, but the effects of this treatment on aortic stenosis progression have not yet been described. The objective of this study was to evaluate whether treatment with nitisinone attenuated the progression of aortic stenosis, as assessed by peak trans-aortic valve pressure (P

Indexed as

alkaptonuriaaortic stenosis (as)metabolic diseasenitisinonetransthoracic echocardiography

Identifiers

PMID41589138
PMCPMC12832065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.